May 30,2007
Sen. Grassley seeks additional information about pricing and marketing of anti-anemia drugs
WASHINGTON --- Sen. Chuck Grassley is asking a leading drug maker to cooperate with his ongoing inquiry into the pricing and marketing of anti-anemia drugs given to kidney and cancer patients and the Food and Drug Administration’s access to data from the drug maker’s studies of such drugs.
The text of the letter Grassley sent today to Johnson & Johnson is below, along with the text of inquiries he made earlier this month and in April of the Food and Drug Administration, Amgen Inc. and the Centers for Medicare and Medicaid Services.
Grassley is Ranking Member of the Senate Committee on Finance.
###
Next Article Previous Article
Recent News
- Wyden Statement on Massive Deficit Impact of Trump IRS Layoffs
- Senate Finance Democrats Demand Hearing to Investigate Trump-Musk Attacks on Social Security
- Wyden, Ross, Castor and Colleagues Propose Criminal Penalties to Fight Fraud, Stop Rogue Insurance Brokers
- Wyden Releases New Information on Financing of Jeffrey Epstein’s operations by Billionaire Leon Black, Seeks Documents from Trump Administration
- Wyden, Schumer, Murray, Senate Democrats Warn Trump and Musk’s Scheme to Fire Social Security Staff Will Disrupt Benefits for Americans